[go: up one dir, main page]

MX375379B - Receptores de celulas t anti - papilomavirus 16 e7 humano. - Google Patents

Receptores de celulas t anti - papilomavirus 16 e7 humano.

Info

Publication number
MX375379B
MX375379B MX2016015383A MX2016015383A MX375379B MX 375379 B MX375379 B MX 375379B MX 2016015383 A MX2016015383 A MX 2016015383A MX 2016015383 A MX2016015383 A MX 2016015383A MX 375379 B MX375379 B MX 375379B
Authority
MX
Mexico
Prior art keywords
hpv
condition
human papillomavirus
mammal
sub
Prior art date
Application number
MX2016015383A
Other languages
English (en)
Other versions
MX2016015383A (es
Inventor
Christian S Hinrichs
Steven A Rosenberg
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MX2016015383A publication Critical patent/MX2016015383A/es
Publication of MX375379B publication Critical patent/MX375379B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)

Abstract

Se describe un receptor de células T (TCR) sintético que tiene especificidad antigénica para un epítopo restringido a HLA-A2 de papilomavirus humano (HPV) 16 E7, E711-19. También se proporcionan polipéptidos relacionados y proteínas relacionadas, así como ácidos nucleicos relacionados, vectores de expresión recombinante relacionados, células hospedadoras recombinantes y poblaciones de células relacionadas. También se proporcionan anticuerpos o una porción de unión a antígeno de estos y composiciones farmacéuticas que se refieren a los TCR de la invención. También se describen métodos para detectar la presencia de una condición en un mamífero y métodos para tratar o prevenir una condición en un mamífero, en donde la condición es cáncer, infección por HPV 16, o premalignidad positiva a HPV.
MX2016015383A 2014-05-29 2015-05-29 Receptores de celulas t anti - papilomavirus 16 e7 humano. MX375379B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462004335P 2014-05-29 2014-05-29
PCT/US2015/033129 WO2015184228A1 (en) 2014-05-29 2015-05-29 Anti-human papillomavirus 16 e7 t cell receptors

Publications (2)

Publication Number Publication Date
MX2016015383A MX2016015383A (es) 2017-02-28
MX375379B true MX375379B (es) 2025-03-06

Family

ID=53396593

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016015383A MX375379B (es) 2014-05-29 2015-05-29 Receptores de celulas t anti - papilomavirus 16 e7 humano.
MX2020010035A MX2020010035A (es) 2014-05-29 2016-11-24 Receptores de celulas t anti-papilomavirus 16 e7 humano.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010035A MX2020010035A (es) 2014-05-29 2016-11-24 Receptores de celulas t anti-papilomavirus 16 e7 humano.

Country Status (21)

Country Link
US (4) US10174098B2 (es)
EP (3) EP3689900B1 (es)
JP (5) JP6742991B2 (es)
KR (2) KR102445667B1 (es)
CN (2) CN106661098B (es)
AU (5) AU2015266818B2 (es)
BR (1) BR112016027805A2 (es)
CA (1) CA2950192A1 (es)
CY (1) CY1122790T1 (es)
DK (1) DK3149031T3 (es)
ES (1) ES2784237T3 (es)
HR (1) HRP20200376T1 (es)
IL (3) IL290655B2 (es)
LT (1) LT3149031T (es)
MX (2) MX375379B (es)
PL (1) PL3149031T3 (es)
PT (1) PT3149031T (es)
SA (1) SA516380394B1 (es)
SI (1) SI3149031T1 (es)
SM (1) SMT202000143T1 (es)
WO (1) WO2015184228A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184228A1 (en) * 2014-05-29 2015-12-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human papillomavirus 16 e7 t cell receptors
US10544392B2 (en) * 2015-05-01 2020-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
MX2018006789A (es) 2015-12-03 2019-02-13 Juno Therapeutics Inc Receptores quimericos modificados y composiciones y metodos relacionados.
US10975436B2 (en) 2016-01-05 2021-04-13 Diamir, Llc Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
CA3035080A1 (en) 2016-09-27 2018-04-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
AU2017338827B2 (en) * 2016-10-03 2023-08-31 Juno Therapeutics, Inc. HPV-specific binding molecules
AU2017366739B2 (en) * 2016-12-02 2023-11-23 Angeles Therapeutics, Inc. Synthetic immune receptors and methods of use thereof
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
CN110650975B (zh) * 2017-05-15 2024-04-05 美国卫生和人力服务部 双顺反子嵌合抗原受体及其用途
US10806780B2 (en) * 2017-06-28 2020-10-20 Regeneron Pharmaceuticals, Inc. Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
AU2018341244A1 (en) 2017-09-26 2020-03-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules and methods of use
MX421596B (es) 2017-09-29 2025-03-14 Us Health Receptores de celulas t que reconocen p53 mutado
US11952408B2 (en) * 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
EP4269595A3 (en) * 2017-10-05 2023-12-06 The United States of America, as represented by the Secretary, Department of Health and Human Services Methods for selectively expanding cells expressing a tcr with a murine constant region
WO2019090202A1 (en) 2017-11-06 2019-05-09 Editas Medicine, Inc. Methods, compositions and components for crispr-cas9 editing of cblb in t cells for immunotherapy
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
CN118374524A (zh) 2018-02-09 2024-07-23 美国卫生和人力服务部 拴系白细胞介素-15和白细胞介素-21
CN112218887B (zh) 2018-03-28 2025-12-12 森罗治疗控股公司 细胞免疫疗法组合物及其用途
MX2020010235A (es) * 2018-03-28 2020-10-28 Cero Therapeutics Inc Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
WO2019191334A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
MA52656A (fr) 2018-04-05 2021-02-17 Editas Medicine Inc Procédés de production de cellules exprimant un récepteur recombinant et compositions associées
MX2020010460A (es) * 2018-04-05 2021-01-29 Juno Therapeutics Inc Receptores de células t, y células diseñadas que expresan los mismos.
EP3775237A1 (en) 2018-04-05 2021-02-17 Juno Therapeutics, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
CN118726256A (zh) 2018-04-24 2024-10-01 美国卫生和人力服务部 使用羟基柠檬酸和/或其盐产生t细胞群体的方法
WO2019243888A1 (en) * 2018-06-22 2019-12-26 Kite Pharma Eu B.V. Compositions and methods for making engineered t cells
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CN113474450A (zh) 2018-08-09 2021-10-01 朱诺治疗学股份有限公司 产生工程化细胞的方法以及所述工程化细胞的组合物
US12366580B2 (en) 2018-09-11 2025-07-22 Juno Therapeutics, Inc. Methods for mass spectrometry analysis of engineered cell compositions
CA3120868A1 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
WO2020214957A1 (en) 2019-04-19 2020-10-22 Tcrcure Biopharma Corp. Anti-pd-1 antibodies and uses thereof
US20220184131A1 (en) 2019-05-01 2022-06-16 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
EP3986450A4 (en) * 2019-06-20 2023-06-28 Memorial Sloan Kettering Cancer Center T cell receptors targeting pik3ca mutations and uses thereof
CN114341171A (zh) 2019-06-27 2022-04-12 美国卫生和人力服务部 识别p53中的r175h或y220c突变的t细胞受体
CN110357952B (zh) * 2019-07-17 2022-03-22 深圳市因诺转化医学研究院 识别人乳头瘤病毒hpv16-e7抗原的tcr
AU2020408017A1 (en) 2019-12-20 2022-07-14 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
CN116034113A (zh) * 2019-12-30 2023-04-28 华夏英泰（北京）生物技术有限公司 一种增强型t细胞受体star及其应用
JP2023509708A (ja) 2020-01-03 2023-03-09 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
CN113072635B (zh) * 2020-01-06 2023-08-25 香雪生命科学技术（广东）有限公司 一种识别hpv抗原的t细胞受体及其编码序列
US20240148869A1 (en) * 2020-05-07 2024-05-09 China Immunotech (Beijing) Biotechnology Co., Ltd Improved T cell receptor-costimulatory molecule chimera
CN115715299A (zh) * 2020-05-25 2023-02-24 华夏英泰（北京）生物技术有限公司 增强型合成t细胞受体抗原受体
US20230227526A1 (en) * 2020-06-09 2023-07-20 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
KR20230042283A (ko) 2020-06-26 2023-03-28 주노 테라퓨틱스 게엠베하 재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법
GB2614166A (en) 2020-09-04 2023-06-28 Us Health T cell receptors recognizing R273C or Y220C mutations in P53
WO2022060904A1 (en) * 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
WO2022104035A2 (en) 2020-11-13 2022-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
BR112023022765A2 (pt) 2021-05-05 2024-01-02 Immatics Biotechnologies Gmbh Proteínas de ligação ao antígeno que ligam especificamente o prame
EP4334340A1 (en) 2021-05-07 2024-03-13 The United States of America, as represented by the Secretary, Department of Health and Human Services T cell receptors recognizing c135y, r175h, or m237i mutation in p53
CN117897411A (zh) * 2021-06-30 2024-04-16 华夏英泰（北京）生物技术有限公司 一种多靶点合成t细胞受体抗原/抗体受体及其应用
JP2024535781A (ja) * 2021-09-07 2024-10-02 コレジェネ バイオテクノロジー カンパニー リミテッド 抗原結合タンパク質およびその使用
WO2023069933A2 (en) * 2021-10-18 2023-04-27 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
TW202325722A (zh) * 2021-11-10 2023-07-01 美商帝斯肯醫療公司 識別ｈｐｖ１６ ｅ７抗原之結合蛋白及其用途
CA3247927A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
CA3247928A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
EP4490173A1 (en) 2022-03-07 2025-01-15 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)
CN117402232A (zh) * 2022-05-10 2024-01-16 广州医科大学 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr
CA3268005A1 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems and methods of T lymphocyte function modulation
CN116731155B (zh) * 2022-09-21 2024-03-22 新景智源生物科技(苏州)有限公司 人乳头瘤病毒特异性t细胞受体、表达其的细胞和其用途
CN121127261A (zh) 2023-03-27 2025-12-12 美国卫生和人力服务部 靶向p53中y220c或r175h突变的t细胞受体
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025096419A1 (en) * 2023-10-31 2025-05-08 Lyell Immunopharma, Inc. T cells comprising a chimeric antigen receptor targeting transforming growth factor beta and a t cell receptor targeting a tumor antigen, and use thereof
WO2025160480A1 (en) 2024-01-26 2025-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
WO2025193926A1 (en) 2024-03-15 2025-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting e545k or n345k mutation in pik3ca
WO2025250587A1 (en) 2024-05-29 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug-regulatable, inducible cytokine expression

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IN165717B (es) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
WO2006103429A2 (en) * 2005-04-01 2006-10-05 Medigene Limited High affinity hiv t cell receptors
PT2016102E (pt) * 2006-05-03 2012-05-15 Us Gov Health & Human Serv Recetores de célula t quimérica e materiais relacionados e métodos de uso
CA3167595A1 (en) 2007-05-31 2008-12-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
GB0917090D0 (en) * 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CN110511960B (zh) * 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
WO2015184228A1 (en) * 2014-05-29 2015-12-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human papillomavirus 16 e7 t cell receptors

Also Published As

Publication number Publication date
IL290655B1 (en) 2024-01-01
CN113150112B (zh) 2024-02-06
KR20220130267A (ko) 2022-09-26
LT3149031T (lt) 2020-05-25
EP3689900A1 (en) 2020-08-05
EP3149031B1 (en) 2019-12-18
JP2024156861A (ja) 2024-11-06
IL290655A (en) 2022-04-01
JP7291196B2 (ja) 2023-06-14
BR112016027805A2 (pt) 2017-10-24
US20170145070A1 (en) 2017-05-25
JP7744479B2 (ja) 2025-09-25
CN106661098A (zh) 2017-05-10
PL3149031T3 (pl) 2020-08-24
JP2022058360A (ja) 2022-04-12
KR102445667B1 (ko) 2022-09-21
AU2024266702A1 (en) 2024-12-12
JP2021000089A (ja) 2021-01-07
SA516380394B1 (ar) 2021-01-05
US20190085047A1 (en) 2019-03-21
MX2020010035A (es) 2020-10-14
IL282518B (en) 2022-04-01
AU2019283892A1 (en) 2020-01-23
PT3149031T (pt) 2020-03-25
EP3149031A1 (en) 2017-04-05
ES2784237T3 (es) 2020-09-23
US20220372103A1 (en) 2022-11-24
AU2021202227A1 (en) 2021-05-06
WO2015184228A1 (en) 2015-12-03
IL290655B2 (en) 2024-05-01
AU2015266818B2 (en) 2019-10-03
AU2023200608A1 (en) 2023-03-09
US11434272B2 (en) 2022-09-06
JP6997267B2 (ja) 2022-02-04
US20210130432A1 (en) 2021-05-06
EP3689900B1 (en) 2025-07-23
JP2017524372A (ja) 2017-08-31
JP6742991B2 (ja) 2020-08-19
US10870687B2 (en) 2020-12-22
KR102618267B1 (ko) 2023-12-27
KR20170003939A (ko) 2017-01-10
IL282518A (en) 2021-06-30
IL248797B (en) 2021-05-31
CY1122790T1 (el) 2021-05-05
HRP20200376T1 (hr) 2020-08-07
JP2023110036A (ja) 2023-08-08
AU2021202227B2 (en) 2022-11-10
CA2950192A1 (en) 2015-12-03
SI3149031T1 (sl) 2020-07-31
IL248797A0 (en) 2017-01-31
CN106661098B (zh) 2021-05-04
AU2015266818A1 (en) 2016-11-24
SMT202000143T1 (it) 2020-05-08
DK3149031T3 (da) 2020-03-16
CN113150112A (zh) 2021-07-23
MX2016015383A (es) 2017-02-28
AU2023200608B2 (en) 2024-08-22
EP4609876A2 (en) 2025-09-03
AU2019283892B2 (en) 2021-01-28
JP7535158B2 (ja) 2024-08-15
US10174098B2 (en) 2019-01-08

Similar Documents

Publication Publication Date Title
MX375379B (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
MX2024005677A (es) Receptores de celulas t que reconocen p53 mutado.
CA2848209C (en) T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
CR20240019A (es) RECEPTORES DE CÉLULAS T RESTRINGIDAS A HLA DE CLASE II CONTRA RAS MUTADO (Divisional expediente 2020-0150)
EA202091335A1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
EA201790976A1 (ru) Терапевтические вакцины против hpv16
MX395287B (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
EP4032544A3 (en) Novel t cell receptors and immune therapy using the same
MX359903B (es) Proteínas estructurales de una mutación del parvovirus como vacunas.
PH12018501335A1 (en) Novel generation of antigen-specific tcrs
WO2019099723A3 (en) Materials and methods relating to immunogenic epitopes from human papillomavirus
MX2022007902A (es) Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia.
AU2015204503A8 (en) Novel vaccines against HPV and HPV-related diseases
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
MY188083A (en) Recombinant proteins and their therapeutic uses
WO2016077525A3 (en) Human anti-thyroglobulin t cell receptors
TR201905447T4 (tr) Yeni mhc bağımsız tümörle ilişkili antijenler.
WO2013138259A3 (en) Polypeptides for treating and/or limiting influenza infection
Ma et al. Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model
MX374919B (es) ANTÍGENOS Y COMBINACIONES DE ANTÍGENOS PARA USARSE PARA ELEVAR LA RESPUESTA INMUNE CONTRA Haemophilus influenzae.
RU2010125678A (ru) Способ получения рекомбинантной вакцины
WO2015120378A8 (en) Porcine epidemic diarrhea virus (pedv) proteins and antigens
HK1228292A1 (en) Porcine epidemic diarrhea virus (pedv) proteins and antigens

Legal Events

Date Code Title Description
FG Grant or registration